Sign up
Pharma Capital

WeedMD partners with world-renowned Technion-Israel Institute of Technology for cannabis research project

Technion is widely recognized as one of the global leaders in medical cannabis research
cannabis leaves
The project will research the profiles of 25 of WeedMD’s cannabis strains

Canadian marijuana producer and distributor WeedMD Inc (CVE:WMD) has joined the world-renowned Cannabis Database Project led by the Technion-Israel Institute of Technology.

Those in the project will be collaborating in the research of cannabinoid and terpenoid profiles of 25 of WeedMD’s cannabis strains.

READ: WeedMD now selling medical cannabis oil

This data will then be added to an international database that correlates the pharmacological effects of the different strains.

From there, the most effective cannabis treatments - strains, dose and route of administration - for clinical purposes can be determined.

This is the first of several research and development initiatives WeedMD is working on as the firm develops its medical cannabis for both the domestic and global markets.

“We are proud to be at the forefront of investing in cannabis research, awareness and education,” said chief scientific officer Luc Duchesne.

“There are hundreds of cannabis strains available to medical patients, but each of these strains has a unique chemical profile, as well potentially unique medical properties.

“A significant barrier to the standardization of medical cannabis is identifying strains that are effective in the treatment of specific medical conditions and Technion is making ground-breaking discoveries to this effect.”

WeedMD shares rose 3.7% to C$2.26 on Wednesday morning.

Why Invest In WeedMD? Read More Here

Register here to be notified of future WMD Company articles
View full WMD profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.